HUTCHMED (China) Limited has applied to the London Stock Exchange for a block admission of 43.62 million ordinary shares, each with a par value of US$0.10, to be admitted to trading on AIM. Admission is expected to take effect on 11 June 2026.

The new shares will be issued from time to time upon the exercise of options granted under the 2026 Share Option Scheme, approved at the company’s 12 May 2026 annual general meeting. Once issued, the shares will be fully paid and rank pari passu with existing ordinary shares.

Following admission, HUTCHMED’s total issued share capital remains unchanged at 872.34 million ordinary shares, each carrying one voting right, with no shares held in treasury. In compliance with AIM Rule 29, the company will publish six-monthly utilisation updates and monthly statements on any change in total voting rights.

The existing block admission covering 45.77 million shares under the company’s 2015 option scheme remains in force.

HUTCHMED is an innovative, commercial-stage biopharmaceutical company focused on targeted therapies and immunotherapies for cancer and immunological diseases.